(Information sent by the signatory company)
Pharmamel launches a new Pre-IPO capital increase campaign on the platform regulated by the CMNV Capital Cell and advances its roadmap to go public on BME Scaleup
Madrid, April 17, 2024.- The biotechnology spin-off and start-up of the University of Granada, Pharmamel, has developed, patented and tested a new intravenous drug to treat sepsis, the leading cause of hospital death. After demonstrating its efficacy and effectiveness, reducing mortality and hospital stay, the company addresses the important challenge of completing a phase III clinical trial in Europe and the US to subsequently obtain marketing authorization. For this reason, Pharmamel will present on April 24, 2024, at 5:00 p.m., in the Antonio Maura assembly hall of the Madrid Stock Exchange Palace, its new capital increase campaign Pre-IPO go to BME Scaleup in the biotechnological crowdfunding platform regulated by the CNMV, Capital Cell. The biotechnological company, emerged through research carried out at the University of Granada, will launch this campaign with the purpose of obtaining the necessary resources for its next listing on the BME Scaleup and to complete the last clinical stages of its new intravenous drug to treat sepsis, the main cause of hospital death. Biotechnology investors, investment funds, as well as health professionals and the pharmaceutical industry, will meet on the 24th April 2024 at 5:00 p.m. at the Madrid Stock Exchange Palace, in order to learn more about the Pharmamel project and its innovative intravenous treatment against sepsis, as well as the Pre-IPO capital increase campaign. go to BME Scaleup.The event will feature the participation of Daniel Oliver, CEO of Capital Cell, and Jesús González Nieto-Márquez, Managing Director of BME Scaleup and BME Growth, and will follow the following program: 16:45: Accreditation of guests and participants.17:00: Institutional welcome.17:10: Investing in biotechnology. Daniel Oliver, CEO of Capital Cell.17:20: Introduction to BME Scaleup and BME Growth. Jesús González Nieto-Márquez, Managing Director of Pre Market Environment, BME Scaleup and BME Growth.17:40: The role of the Registered Advisor in BME Scaleup and BME Growth María Lago García, General Director of ARMANEXT Registered Advisors. 17:50: Pharmamel: Pre-IPO Go to BME-Scaleup. Ramón García, CEO Pharmamel. Dario Acuña, Scientific Director Pharmamel. Germaine Escames, Pharmamel Scientific Director. *The capital increase campaign is already active privately, with a limited time discount of 15%.: https://capitalcell.es/campaign/pharmamel-2024/Emisor: Pharmamel
Contact Contact name: Pharmamel campaign communication department Contact description: Pharmamel Contact telephone number: 958 41 91 43
